Advertisement

Drug Safety

, Volume 9, Issue 5, pp 346–364 | Cite as

Adverse Effects of Macrolide Antibacterials

  • Piero Periti
  • Teresita Mazzei
  • Enrico Mini
  • Andrea Novelli
Review Article Drug Experience

Summary

The renewed interest in macrolide antibacterials with expanded indications for clinical use, as well as their markedly increased usage, justifies the continuous search for new compounds designed to offer the patient not only enhanced bioavailability but also a reduced incidence of adverse effects.

Macrolides are an old and well established class of antimicrobial agents that account for 10 to 15% of the worldwide oral antibiotic market. Macrolides are considered to be one of the safest anti-infective groups in clinical use, with severe adverse reactions being rare. Newer products with improved features have recently been discovered and developed, maintaining or significantly expanding the role of macrolides in the management of infection. This review deals with the tolerability of the clinically available macrolide antibacterials. With the exception of drug interactions, adverse effects have been analysed during the last 40 years in many thousands of adult and paediatric patients. Recently developed derivatives have been compared with the older compounds, and the expected and well assessed adverse effects have been set apart from those which are unusual, very rare or questionable.

Gastrointestinal reactions represent the most frequent disturbance, occurring in 15 to 20% of patients on erythromycins and in 5% or fewer patients treated with some recently developed macrolide derivatives that seldom or never induce endogenous release of motilin, such as roxithromycin, clarithromycin, dirithromycin, azithromycin and rikamycin (rokitamycin).

Except for troleandomycin and some erythromycins administered at high dose and for long periods of time, the hepatotoxic potential of macrolides, which rarely or never form nitrosoalkanes, is low for josamycin, midecamycin, miocamycin, flurithromycin, clarithromycin and roxithromycin; it is negligible or absent for spiramycin, rikamycin, dirithromycin and azithromycin. Transient deafness and allergic reactions to macrolide antibacterials are highly unusual and have definitely been shown to be more common following treatment with the erythromycins than with the recently developed 14-, 15- and 16-membered macrolides.

There have been case reports in the literature of 51 patients during the last 30 years who experienced uncommon or dubious adverse effects after treatment with older compounds and in which there appears to be strong evidence of a causal relationship with the drug. Only 3 cases had an unfavourable outcome, and these were patients administered erythromycin lactobionate intravenously too rapidly or at high dose. Targets of these occasional reactions are generally the heart, liver and central nervous system. Other unusual organ pathologies are related to immunomediated disorders more than to primary parenchymal toxicity, or to the rarely serious consequences of macrolide-induced alterations in intestinal microflora.

Physicians should be alerted to the possibility of unusual toxicity that could also emerge in the future from the new and recently developed macrolide antibacterials, coinciding with their expanded clinical use worldwide.

Keywords

Erythromycin Azithromycin Roxithromycin Spiramycin Infantile Hypertrophic Pyloric Stenosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Agusti C, Ferràn F, Gea J, Picado C. Ototoxic reaction to erythromycin. Archives of Internal Medicine 151: 380, 1991PubMedGoogle Scholar
  2. Antoniades K, Spector HB, Ebel M, Sorkin H, Smith M. Pseu-domembranous colitis associated with ampicillin and erythromycin therapy: report of a case. Diseases of the Colon and Rectum 21: 514–519, 1978PubMedGoogle Scholar
  3. Avila P, Capella D, Laporte J-R, Moreno V. Which salt of erythromycin is most hepatotoxic? Lancet 14: 1104, 1988Google Scholar
  4. Ball P. The future role and importance of macrolides. Journal of Hospital Infection 19 (Suppl. A): 47–59, 1991PubMedGoogle Scholar
  5. Beckner RR, Gantz N, Hughes JP, Farricy JP. Ototoxicity of erythromycin gluceptate. American Journal of Obstetrics and Gynecology 139: 738–739, 1981PubMedGoogle Scholar
  6. Benoit A, Bodiou C, Villain E, Bavoux F, Checoury A, et al. QT prolongation and circulatory arrest after an injection of erythromycin in a newborn infant. Archives Françaises de Pediatrie 48: 39–41, 1991PubMedGoogle Scholar
  7. Blanc F, D’Enfert J, Fiessinger S, Lenoir A, Renault M, et al. An evaluation of tolerance of roxithromycin in adults. Journal of Antimicrobial Chemotherapy 20 (Suppl. B): 179–183, 1987PubMedGoogle Scholar
  8. Bonino S, Privitera G, Del Mastro S. Ricerca multicentrica sulla efficacia e tollerabilità nell’adulto e nel bambino della josamicina. Giornale Italiano di Chemioterapia 30: 153–159, 1983PubMedGoogle Scholar
  9. Braun P. Hepatotoxicity of erythromycin. Journal of Infectious Diseases 119: 300–306, 1969PubMedGoogle Scholar
  10. Brummett RE, Fox KE. Minireviews. Vancomycin- and eryth-romycin-induced hearing loss in humans. Antimicrobial Agents and Chemotherapy 33: 791–796, 1989PubMedGoogle Scholar
  11. Chelvan P, Hamilton-Miller JM, Brumfitt W. Biliary excretion of erythromycin after parenteral administration. British Journal of Clinical Pharmacology 8: 233–235, 1979PubMedGoogle Scholar
  12. Cohen IJ, Weitz R. Psychiatric complications with erythromycin. Drug Intelligence and Clinical Pharmacy 15: 388, 1981PubMedGoogle Scholar
  13. Daniel R. Azithromycin, erythromycin and cloxacillin in the treatment of infections of skin and associated soft tissues. Journal of International Medical Research 19: 23–35, 1991aGoogle Scholar
  14. Daniel R. Simplified treatment of acute lower respiratory tract infection with azithromycin: a comparison with erythromycin and amoxycillin. Journal of International Medical Research 19: 373–383, 1991bPubMedGoogle Scholar
  15. Davies RJ, Pepys J. Asthma due to inhaled chemical agents — the macrolide antibiotic spiramycin. Clinical Allergy 11: 99–107, 1975Google Scholar
  16. Del Vasto F, Pinta MF, Marchese L, Cimaglia ML, Rivenso G, et al. Anemia emolitica immunitaria farmacoindotta in un paziente di 18 mesi. Agente responsabile: eritromicina. Pediatria Medica e Chirurgica 12: 275–276, 1990PubMedGoogle Scholar
  17. Descotes J, Vial T, Delattre D, Evreux J-C. Spiramycin: safety in man. Journal of Antimicrobial Chemotherapy 22 (Suppl. B): 207–210, 1988PubMedGoogle Scholar
  18. Dylewski J. Irreversible sensorineural hearing loss due to erythromycin. Canadian Medical Association Journal 139: 230–231, 1988PubMedGoogle Scholar
  19. Eckman MR, Johnson T, Riess R. Partial deafness after erythromycin. New England Journal of Medicine 1: 649, 1975Google Scholar
  20. Eichenwald HF. Adverse reactions to erythromycin. Pediatric Infectious Disease 5: 147–150, 1986PubMedGoogle Scholar
  21. Ellsworth AJ, Christensen DB, Volpone-McMahon MT. Prospective comparison of patient tolerance to enteric-coated vs nonenteric-coated erythromycin. Journal of Family Practice 31: 265–270, 1990PubMedGoogle Scholar
  22. Enriquez R, Berisa F, Sanz Moreno C, Salvà M, Sanz Guajardo D, et al. Nefritis intersticial aguda por eritromicina. Medicina Clinica 82: 182–183, 1984PubMedGoogle Scholar
  23. Fernandes PB. The macrolide revival: thirty-five years after erythromycin. Antimicrobial Newsletter 4: 25–34, 1987Google Scholar
  24. Fisher A. Erythromycin ‘free base’ — a nonsensitizing topical antibiotic for infected dermatoses and acne vulgaris. Contact Dermatitis 20: 17–35, 1977Google Scholar
  25. Florido Lopez JF, Lopez Serrano MC, Belchi Hernandez J, Estrada Rodriguez JL. Fixed eruption due to erythromycin. Allergy 46: 77–78, 1991PubMedGoogle Scholar
  26. Franklin MR. Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Methods in Enzymology 206: 559–573, 1991PubMedGoogle Scholar
  27. Freedman RA, Anderson KP, Green LS, Mason JW. Effect of erythromycin on ventricular arrhythmias and ventricular repolarization in idiopathic long QT syndrome. American Journal of Cardiology 59: 168–169, 1987PubMedGoogle Scholar
  28. Funck-Brentano C, Pessayre D, Benhamou J-P. Hépatites dues a divers dérivés de l’érythromycine. Gastroenterology and Clinical Biology 7: 362–369, 1983Google Scholar
  29. Gantz NM, Zawacki JK, Dickerson WJ, Bartlett J. Pseudomem-branous colitis associated with erythromycin. Annals of Internal Medicine 91: 866–867, 1979PubMedGoogle Scholar
  30. Gholson CF, Warren GH. Fulminant hepatic failure associated with intravenous erythromycin lactobionate. Archives of Internal Medicine 150: 215–216, 1990PubMedGoogle Scholar
  31. Gilbert FI. Cholestatic hepatitis caused by esters of erythromycin and oleandomycin. Journal of the American Medical Association 182: 1048–1050, 1962PubMedGoogle Scholar
  32. Guegniaud PY, Guerin C, Mahul P, Due C, Robert D. Torsades de pointes induites par l’association lidocaine-erythromycine et insuffisance hépatique. Presse Médicale 14: 896, 1985Google Scholar
  33. Guelon D, Bedock B, Chartier C, Haberer J-P. QT prolungation and recurrent ‘torsades de pointes’ during erythromycin lactobionate infusion. American Journal of Cardiology 54: 666, 1984Google Scholar
  34. Gumaste VV. Erythromycin-induced pancreatitis. American Journal of Medicine 86: 725, 1989aPubMedGoogle Scholar
  35. Gumaste VV. Acute pancreatitis induced by erythromycin. American Journal of Medicine 87: 701, 1989bGoogle Scholar
  36. Handa SP. The Schönlein-Henoch syndrome: glomerulonephritis following erythromycin. Southern Medical Journal 65: 917–920, 1972PubMedGoogle Scholar
  37. Hara K. Rokitamycin. Japanese Journal of Antibiotics 40: 1851–1866, 1987PubMedGoogle Scholar
  38. Hardy DJ, Guay DRP, Jones RN. Clarithromycin, a unique macrolide. A pharmacokinetic, microbiological, and clinical overview. Diagnostic Microbiology and Infectious Diseases 15: 39–53, 1992Google Scholar
  39. Hassel B. Hypothermia from erythromycin. Annals of Internal Medicine 115: 69–70, 1991PubMedGoogle Scholar
  40. Hawksworth CRE. Acute pancreatitis associated with infusion of erythromycin lactobionate. British Medical Journal 298: 190, 1989PubMedGoogle Scholar
  41. Haydon RC, Thelin JW, Davis WE. Erythromycin ototoxicity: analysis and conclusions based on 22 case reports. Otolaryngology-Head and Neck Surgery 92: 678–684, 1984PubMedGoogle Scholar
  42. Heimdahl A, Nord CE. Influence of erythromycin on the normal human flora and colonization of the oral cavity, throat and colon. Scandinavian Journal of Infectious Diseases 14: 49–56, 1982PubMedGoogle Scholar
  43. Herishanu Y, Taustein I. The electromyographic changes induced by antibiotics: a preliminary study. Confinia Neurologica 33: 41–45, 1971PubMedGoogle Scholar
  44. Heyman SN, Stalnikowicz R, Heyman A, Gilon D, Mogle P. Erythromycin-induced dynamic ileus? Journal of Clinical Gastroenterology 10: 551–554, 1988PubMedGoogle Scholar
  45. Holland BR, Quay JF. Intestinal secretion of erythromycin base. Journal of Pharmaceutical Sciences 65: 417–419, 1976PubMedGoogle Scholar
  46. Hopkins S. Clinical toleration and safety of azithromycin. American Journal of Medicine 91 (Suppl. 3A): 40S–45S, 1991PubMedGoogle Scholar
  47. Horsmans Y, Larrey D, Pessayre D, Benhamou J-P. Hépatotoxicité des médicaments anti-infectieux. Première partie: les antibiotiques anti-bactériens. Gastroenterology and Clinical Biology 14: 911–918, 1990Google Scholar
  48. Inman WHW, Rawson NSB. Erythromycin estolate and jaundice. British Medical Journal 286: 1954–1955, 1983PubMedGoogle Scholar
  49. Israel D, Polk RE. Recently described adverse reactions to antimicrobials. Current Opinion in Infectious Diseases 3: 773–779, 1990Google Scholar
  50. Itoh Z, Suzuki T, Nakaya M, Inoue M, Arai H, Wakabayashi K. Structure-activity relation among macrolide antibiotics in initiation of interdigestive migrating contractions in the canine gastrointestinal tract. American Journal of Physiology 248: G320–G325, 1985PubMedGoogle Scholar
  51. Itoh Z. Effect of rokitamycin on upper gastrointestinal contractile activity. Analysis of side-effects on gastrointestinal tract. Japanese Journal of Antibiotics 41: 823–829, 1988PubMedGoogle Scholar
  52. Itoh Z, Nakaya M, Suzuki T, Arai H, Wakabayashi K. Erythromycin mimics exogenous motilin in gastrointestinal contractile activity in the dog. American Journal of Physiology 247: G688–G694, 1984aPubMedGoogle Scholar
  53. Itoh Z, Suzuki T, Nakaya M, Inoue M, Mitsuhashi S. Gastrointestinal motor-stimulating activity of macrolide antibiotics and analysis of their side effects on the canine gut. Antimicrobial Agents and Chemotherapy 26: 863–869, 1984bPubMedGoogle Scholar
  54. Jars N, Hardy N, Salhi A. Review of clinical experience with midecamycin in France. Proceedings of the 12th International Congress of Chemotherapy, Florence, July 19–24, 1981. In Periti & Gialdroni Grassi (Eds) Current chemotherapy and immunotherapy, Vol. 2, American Society for Microbiology, Washington, DC, 1982Google Scholar
  55. Kafetzis DA, Blanc F. Efficacy and safety of roxithromycin in treating paediatric patients. A European multicentre study. Journal of Antimicrobial Chemotherapy 20 (Suppl. B): 171–177, 1987PubMedGoogle Scholar
  56. Kanfer A, Daniel F, Vigeral Ph, Méry J-Ph. Oto-toxicité de l’érithromycine au cours de l’insuffisance rénale chronique. Thérapie 35: 365–367, 1980PubMedGoogle Scholar
  57. Kanfer A, Daniel F, Vigeral Ph, Méry J-Ph, Haguet JF. Surdité transitoire chez des insuffisants rénaux traités par l’érythromycine. Nouvelle Presse Médicale 27: 2283–2284, 1979Google Scholar
  58. Kanwar AJ, Bharija SC, Belhaj MS. Fixed drug eruptions in children: a series of 23 cases with provocative tests. Dermatologica 172: 315–318, 1986PubMedGoogle Scholar
  59. Kirst HA. New macrolides: expanded horizons for an old class of antibiotics. Journal of Antimicrobial Chemotherapy 28: 787–790, 1991PubMedGoogle Scholar
  60. Kirst HA, Sides GD. New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrobial Agents and Chemotherapy 33: 1419–1422, 1989PubMedGoogle Scholar
  61. Kofoed ML, Oxholm A. Toxic epidermal necrolysis due to erythromycin. Contact Dermatitis 13: 273, 1985Google Scholar
  62. Kroboth PD, McNeil M, Kreeger A, Dominguez J, Rault R. Hearing loss and erythromycin pharmacokinetics in a patient receiving hemodialysis. Archives of Internal Medicine 143: 1263–1265, 1983PubMedGoogle Scholar
  63. Kuder HV. Propionyl erythromycin. A review of 20,252 case reports for side effect data. Clinical Pharmacology and Therapeutics 1: 604–609, 1960PubMedGoogle Scholar
  64. Larrey D, Amouyal G, Danan G, Degott C, Pessayre D, Benhamou J-P. Prolonged cholestasis after trolenadomycin-induced acute hepatitis. Journal of Hepatology 4: 327–329, 1987PubMedGoogle Scholar
  65. Lavarenne J, Dumas R, Maradeix B, Fialip J. Hépatites au cours de l’antibiothérapie. Bilan rétrospectif de l’Association des Centres de Pharmacovigilance et du Bureau de la Pharmaco-vigilance D.P.H.M., Ministère de la Santé. Thérapie 39: 517–522, 1984PubMedGoogle Scholar
  66. Lehtola J, Jauhonen P, Kesäniemi A, Wikberg R, Gordin A. Effect of erythromycin on the oro-caecal transit time in man. European Journal of Clinical Pharmacology 39: 555–558, 1990PubMedGoogle Scholar
  67. Lehtonen L, Lankinen KS, Wikberg R, Rita H, Salmi HA, Valtonen V. Hepatic safety of erythromycin acistrate in 1549 patients with respiratory tract or skin infection. Journal of Antimicrobial Chemotherapy 27: 233–242, 1991PubMedGoogle Scholar
  68. Levin G, Behrenth E. Irreversible ototoxic effect of erythromycin. Scandinavian Audiology 15: 41–42, 1986PubMedGoogle Scholar
  69. Lindsay J, Smith MA, Light JA. Torsades de pointes associated with antimicrobial therapy for pneumonia. Chest 98: 222–223, 1990PubMedGoogle Scholar
  70. Lombardi P, Campolmo P, Spallanzani P, Sertoli A. Delayed hypersensitivity to erythromycin. Contact Dermatitis 8: 416–431, 1982PubMedGoogle Scholar
  71. Lornoy W, Steyaert J. Ototoxicity of erythromycin lactobionate. Acta Clinica Belgica 34: 111, 1979PubMedGoogle Scholar
  72. Malmborg AS. The renaissance of erythromycin. Journal of Antimicrobial Chemotherapy 18: 293–299, 1986PubMedGoogle Scholar
  73. Manian FA, Stone WJ, Alford RH. Adverse antibiotic effects associated with renal insufficiency. Reviews of Infectious Diseases 12: 236–249, 1990PubMedGoogle Scholar
  74. Marlin GE, Thompson PJ, Jenkins CR, Burgess KR, LaFranier DAJ. Study serum levels, venous irritation and gastrointestinal side-effects with intravenous erythromycin lactobionate in patients with bronchopulmonary infection. Human Toxicology 2: 593–605, 1983PubMedGoogle Scholar
  75. May EF, Calvert PC. Aggravation of myasthenia gravis by erythromycin. Annals of Neurology 28: 577–579, 1990PubMedGoogle Scholar
  76. Mayama T, Maruyama K, Nakazawa T, Iida M. A survey of the side effects of midecamycin acetate (Miocamycin) dry syrup after marketing. International Journal of Clinical Pharmacology, Therapy and Toxicology 28: 245–250, 1990Google Scholar
  77. McComb JM, Campbell NPS, Cleland J. Recurrent ventricular tachycardia associated with QT prolongation after mitral valve replacement and its association with intravenous administration of erythromycin. American Journal of Cardiology 54: 922–923, 1984PubMedGoogle Scholar
  78. Méry J-Ph, Kanfer A. Ototoxicity of erythromycin in patients with renal insufficiency. New England Journal of Medicine 301: 944, 1979PubMedGoogle Scholar
  79. Méry J-Ph, Kanfer A. Erythromycin-induced ototoxicity. Mayo Clinic Proceedings 58: 401, 1983PubMedGoogle Scholar
  80. Mintz U, Amir J, Pinkhas J, de Vries A. Transient perceptive deafness due to erythromycin lactobionate. Journal of the American Medical Association 225: 1122–1123, 1973PubMedGoogle Scholar
  81. Miura T, Iwasaki M, Komori M, Ohi H, Kitadu M, et al. Decrease in a constitutive form of cytochrome P-450 by macrolide antibiotics. Journal of Antimicrobial Chemotherapy 24: 551–559, 1989PubMedGoogle Scholar
  82. Motohiro T, Sakata Y, Shimada Y, Koga T, Yamashita F. Effect of TMS-19-W (rokitamycin), a new macrolide antibiotic, on bacterial flora in human feces. Proceedings of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, 4–7 October 1987, American Society for Microbiology, Washington, DC, 1987Google Scholar
  83. Naik RPC, Singh G. Bullous fixed drug eruption presumably due to erythromycin. Dermatologica 152: 177–180, 1976PubMedGoogle Scholar
  84. Nakayoshi T, Izumi M, Shinkai S, Fujita M. Comparative study on effects of 14- and 16-membered macrolides on gastrointestinal motility in unanaesthetized dogs. Drugs Under Experimental and Clinical Research 14: 319–325, 1988PubMedGoogle Scholar
  85. Nakazawa S, Sato H, Chikaoka H. Clinical evaluation of midecamycin. Proceedings of the 12th International Congress of Chemotherapy, Florence, July 19–24, 1981. In Periti & Gialdroni Grassi (Eds) Current chemotherapy and immunotherapy, Vol. 2, American Society for Microbiology, Washington, DC, 1982Google Scholar
  86. Nance SJ, Ladisch S, Williamson TL, Garratty G. Erythromycin-induced immune hemolytic anemia. Vox Sanguinis 55: 233–236, 1988PubMedGoogle Scholar
  87. Nattel S, Ranger S, Talajic M, Lemery R, Roy D. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism. American Journal of Medicine 89: 235–238, 1990PubMedGoogle Scholar
  88. Neu HC. The development of macrolides: clarithromycin in perspective. Journal of Antimicrobial Chemotherapy 27 (Suppl. A): 1–9, 1991PubMedGoogle Scholar
  89. Neu HC. New macrolide antibiotics: azithromycin and clarithromycin. Annals of Internal Medicine 116: 517–519, 1992PubMedGoogle Scholar
  90. Neuberger F, Davis M. Immune mechanisms in drug-induced liver injury. Recent Advances in Hepatology 1: 89–100, 1983Google Scholar
  91. Omura S, Tsuzuki K, Sunazuka T, Toyota H, Takahashi I, et al. Gastrointestinal motor-stimulating activity of macrolide antibiotics and the structure-activity relationship. Journal of Antibiotics 38: 1631–1632, 1985PubMedGoogle Scholar
  92. O’Neill SJ, Millar ED, Coles SJ, Bachand RT. Safety and efficacy of clarithromycin in the treatment of acute mild to moderate respiratory tract infections. Irish Medical Journal 84: 33–35, 1991PubMedGoogle Scholar
  93. Pendleton N, Mallik LJ, Williams JG. Erythromycin rash in glandular fever. British Journal of Clinical Practice 43: 464–465, 1989PubMedGoogle Scholar
  94. Periti P, Mazzei T, Mini E, Novelli A. Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states Part I–II. Clinical Pharmacology 16: 193–214 & 261–282, 1989Google Scholar
  95. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clinical Pharmacokinetics 23: 106–131,1992PubMedGoogle Scholar
  96. Perreard M, Klotz F. Esophagite ulcérée après prise de spiramycine. Annales des Gastroentérologie et Hépatologie 25: 313–314, 1989Google Scholar
  97. Pessayre D, Larrey D, Funck-Brentano C, Benhamou JP. Drug interactions and hepatitis produced by some macrolide antibiotics. Journal of Antimicrobial Chemotherapy 16 (Suppl. A): 181–194, 1985PubMedGoogle Scholar
  98. Peters DH, Clissold SP. Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 44: 117–164, 1992PubMedGoogle Scholar
  99. Pigatto PD, Riboldi A, Riva F, Altomare GF. Fixed drug eruption to erythromycin. Acta Dermatologica Venereologica 64: 272–273, 1984Google Scholar
  100. Pilot MA, Qin XY. Macrolides and gastrointestinal motility. Journal of Antimicrobial Chemotherapy 22 (Suppl. B): 201–206, 1988PubMedGoogle Scholar
  101. Pilot MA, Ritchie HD, Thompson HH, Zara GP. Alterations in gastrointestinal motility associated with erythromycin. British Journal of Pharmacology 81: 168, 1984Google Scholar
  102. Ponsonnaille J, Citron B, Richard A, Trolese JF, Chaperon A, et al. Etude électrophysiologique des effets pro-arythmogènes de l’érythromycine. Archives des Maladies du Coeur et des Vaisseaux 81: 1001–1008, 1988PubMedGoogle Scholar
  103. Ponte CD, Arbogast JG, Liebig CW. Pseudomembranous colitis: a case report and literature review. West Virginia Medical Journal 80: 117–121, 1984PubMedGoogle Scholar
  104. Popper H, Rubin E, Gardiol D. Drug-induced liver disease. Archives of Internal Medicine 115: 128–136, 1965PubMedGoogle Scholar
  105. Portier H, Chavanet P. Les macrolides aujourd’hui. Leur large utilisation en pratique courante est justifiée. Revue du Practicien 41: 2065–2067, 1991Google Scholar
  106. Privitera G, Bonino S, Del Mastro S. La josamicina nel trattamento dell’acne volgare. Risultati di uno studio multicentrico su 745 pazienti. Giornale Italiano di Dermatologia e Vener-eologia 123: 23–28, 1988Google Scholar
  107. Qin XY, Pilot M-A, Thompson HH, Maskell JP. Comparison of the side effects and gastrointestinal motility observed after administration of erythromycin and josamycin to dogs. Journal of Antimicrobial Chemotherapy 18: 747–756, 1986PubMedGoogle Scholar
  108. Quinnan GV, McCabe WR. Ototoxicity of erythromycin. Lancet 1: 1160–1161, 1978PubMedGoogle Scholar
  109. Robinson MM. Antibiotics increase incidence of hepatitis. Journal of the American Medical Association 178: 89–92, 1961Google Scholar
  110. Sabath LD, Gerstein DA, Finland M. Serum glutamic oxalacetic transaminase: false elevations during administration of erythromycin. New England Journal of Medicine 279: 1137–1139, 1968PubMedGoogle Scholar
  111. Sacristàn JA, Soto J, De Cos MA. Erythromycin-induced hearing loss. Lancet 2: 1080, 1990Google Scholar
  112. SanFilippo JA. Infantile hypertrophic pyloric stenosis related to ingestion of erythromycin estolate: a report of five cases. Journal of Pédiatric Surgery 11: 177–180, 1976PubMedGoogle Scholar
  113. Schachner L, Pestana A, Kittles C. A clinical trial comparing the safety and efficacy of a topical erythromycin-zinc formulation with a topical clindamycin formulation. Journal of the American Academy of Dermatology 22: 489–495, 1990PubMedGoogle Scholar
  114. Schlegel PN, Chang TSK, Marshall FF. Antibiotics: potential hazards to male fertility. Fertility and Sterility 55: 235–242, 1991PubMedGoogle Scholar
  115. Schoenenberger RA, Haefeli WE, Weiss P, Ritz RF. Association of intravenous erythromycin and potentially fatal ventricular tachycardia with QT prolongation (torsades de pointes). British Medical Journal 300: 1375–1376, 1990PubMedGoogle Scholar
  116. Schweitzer VG, Olson NR. Ototoxic effect of erythromycin therapy. Archives of Otolaryngology 110: 258–260, 1984PubMedGoogle Scholar
  117. Seifert CF, Swaney RJ, Bellanger-McCleery RA. Entravenous erythromycin lactobionate-induced severe nausea and vomiting. Annals of Pharmacotherapy 23: 40–44, 1989PubMedGoogle Scholar
  118. Sides GD, Conforti PM. Safety profile of dirithromycin. Journal of Antimicrobial Chemotherapy 31 (Suppl. C): 175–185, 1993PubMedGoogle Scholar
  119. Taylor R, Schofield IS, Ramos JM, Bint AJ, Ward MK. Ototoxicity of erythromycin in peritoneal dialysis patients. Lancet 2: 935–936, 1981PubMedGoogle Scholar
  120. Teillet L, Chaussade S, Mory B, Roche H, Couturier D, et al. Pancréatite aigue associée à une antibiothérapie par l’érythromycine intraveineuse. Gastroenterologie Clinique et Biologique 15: 265–266, 1991PubMedGoogle Scholar
  121. Ticktin HE, Zimmerman HJ. Hepatic dysfunction and jaundice in patients receiving triacetyloleandomycin. New England Journal of Medicine 267: 964–968, 1962Google Scholar
  122. Umstead GS, Neumann KH. Erythromycin ototoxicity and acute psychotic reaction in cancer patients with hepatic dysfunction. Archives of Internal Medicine 146: 897–899, 1986PubMedGoogle Scholar
  123. Van Ketel VG. Immediate- and delayed-type allergy to erythromycin. Contact Dermatitis 2: 363–364, 1976PubMedGoogle Scholar
  124. Washington JA, Wilson WR. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (second of two parts). Mayo Clinic Proceedings 60: 271–278, 1985PubMedGoogle Scholar
  125. Whitener CJ, Parker JE, Lapp NL. Erythromycin ototoxicity: a call to heighten recognition. Southern Medical Journal 84: 1214–1216, 1991PubMedGoogle Scholar
  126. Williams NR. Erythromycin: a case of nightmares. British Medical Journal of Clinical Research 296: 214, 1988Google Scholar
  127. Wong KY, Boose GM, Issitt CH. Erythromycin-induced hemolytic anemia. Journal of Pediatrics 98: 647–649, 1981PubMedGoogle Scholar
  128. Wood MJ. The tolerance and toxicity of clarithromycin. Journal of Hospital Infections 19 (Suppl. A): 39–46, 1991Google Scholar
  129. Young RA, Gonzales JP, Sorkin EM. Roxithromycin: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 37: 8–41, 1989PubMedGoogle Scholar
  130. Zafrani ES, Ishak KG, Rudzki C. Cholestatic and hepatocellular injury associated with erythromycin esters: a report of 9 cases. Digestive Diseases and Sciences 24: 385–396, 1979PubMedGoogle Scholar
  131. Zara GP, Thompson HH, Pilot MA, Ritchie HD. Effects of erythromycin on gastrointestinal tract motility. Journal of Antimicrobial Chemotherapy 16 (Suppl. A): 175–179, 1985PubMedGoogle Scholar
  132. Zara GP, Quin XY, Pilot MA, Thomson HH, Maskell JP. Erythromycin and gastrointestinal motility. Lancet 2: 1036, 1987PubMedGoogle Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • Piero Periti
    • 1
  • Teresita Mazzei
    • 1
  • Enrico Mini
    • 1
  • Andrea Novelli
    • 1
  1. 1.Department of Preclinical and Clinical PharmacologyUniversity of FlorenceFlorenceItaly

Personalised recommendations